Le Lézard
Classified in: Health, Science and technology, Business
Subjects: TNM, LIC

Imbio to be Acquired by 4DMedical Creating Comprehensive Cardiothoracic Image Analysis Portfolio


Acquisition by global medical company advances powerful analytical imaging technology

MINNEAPOLIS, Dec. 11, 2023 /PRNewswire/ -- Imbio, Inc. (a portfolio company of Minneapolis-based Invenshure LLC), a provider of medical imaging analysis technologies for chronic lung and cardiothoracic diseases, announces it has entered a binding agreement to be acquired by 4DMedical, a leading producer of advanced lung function imaging software. The combined technology offering will turn any standard chest CT into a much broader Cardiothoracic Analysis, immediately providing functional, structural, and risk-based analysis for both lung and heart disease.

Imbio's technology provides quantitative and personalized imaging analysis for patients with acute and chronic diseases. The automated system transforms chest CT studies into visual lung maps, generating detailed reports on abnormalities. Imbio algorithms support various clinical initiatives, including lung cancer screening, smoking cessation, surgical planning, and pulmonary embolism management. Additionally, they are leveraged in clinical trials and academic research for diverse diseases.

"Imbio is very excited to join forces with 4DMedical to create the leading lung imaging AI suite in the market, combining 4DMedical's functional analysis with Imbio's anatomical and tissue analysis. Together we can help clinicians around the globe detect disease earlier, make more robust diagnosis, and drive more informed and confident decision-making for better patient care," said Dave Hannes, CEO at Imbio.

"This merger represents the culmination of a multi-year effort by Invenshure to create and build Imbio into a preeminent healthcare technology company. Partnering with 4DMedical to create a unified offering and platform will maximize patient impact and shareholder value," said Danny Cunagin, Chairman of Imbio and Co-CEO of Invenshure.

"I am extremely excited to join forces with the incredibly talented and committed Imbio team. Imbio's market-leading suite of AI solutions provide life-changing insights from CT scans, and perfectly complements 4DMedical's functional imaging technology," says Andreas Fouras, Founder and CEO of 4DMedical. "We now offer a comprehensive cardiothoracic imaging solution set to providers and their patients. Importantly, the Imbio acquisition also boosts our commitment to improve veteran pulmonary health care?especially for those impacted by toxic exposures during service."

About Imbio

Imbio is a leader in artificial intelligence (AI) medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalized care for patients. Learn more at www.imbio.com

About Invenshure

Founded by tech veterans Danny Cunagin and Troy Kopischke, Invenshure is a venture studio that transforms challenging problems into successful companies. Specializing in high-growth sectors such as biotech, genomics, healthcare IT, diagnostics, cloud computing, and wireless technologies, Invenshure delivers returns to investors and contributes to overall betterment. Learn more at www.invenshure.com.

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®)  ?  the first modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS®.

XV LVAS and CT LVAS reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner. To learn more, please visit www.4dmedical.com.

SOURCE Imbio, Inc.


These press releases may also interest you

29 jun 2024
Supreme Court Justice Alito referenced The PPROM Foundation this past week in his dissenting opinion on Moyle v. United States and Idaho v. United States. The PPROM Foundation is a national non-profit organization dedicated to supporting families...

29 jun 2024
"His Holiness the Dalai Lama underwent  successful knee replacement surgery on Friday, June 28, at Hospital for Special Surgery," said David J. Mayman, MD, Chief of the Adult Reconstruction and Joint Replacement Service at HSS. "He is expected to...

29 jun 2024
Multi-Media Release/Press Kit Black Girl...

29 jun 2024
Kyowa Hakko Bio Co., Ltd. and Kirin Holdings Company, Limited are thrilled to announce their sponsored satellite program at the American Society for Nutrition's (ASN) Annual Conference, NUTRITION 2024. This groundbreaking session will spotlight the...

29 jun 2024
30% of youth in foster care identify as LGBTQ, a rate nearly three times higher than those not in the foster care system. There are five times more transgender youth in foster care than in the general population. Wayfinder Family Services, one of the...

28 jun 2024
Psych Associates of Maryland LLC d/b/a Bloom Health Centers ("Bloom Health"), a mental health service provider, has learned of a data security incident that may have involved the personal and protected health information of certain individuals. This...



News published on and distributed by: